Doi: 10.1038/aps.2017.66

S3.1

Synergistic effect of Astragalus flavonoids on breast cancer chemotherapeutic agent cyclophosphamide based on the regulation of immune function

Jing WANG, Xiao LI, Yan-shuang QI, Jia-hui NIE, Xue-mei QIN*

Modern Research Center for Traditional Chinese Medicine, Shanxi University, Taiyuan 030006, China

*To whom correspondence should be addressed.

E-mail: qinxm@sxu.edu.cn

The present study aimed to observe the synergistic effect of Astragalus flavonoids (TFA) on breast cancer chemotherapeutic agent cyclophosphamide (CTX) and its effect on immunologic function. 4T1 breast cancer bearing mice were established and then randomly into control group, model group, CTX group (80 mg/kg), CTX (80 mg/kg) combined with TFA (6 mg/kg) group and TFA group (6 mg/kg). After 3 weeks of different treatments, tumor inhibition rates were measured; subpopulation of the splenic lymphocytes and marrow derived suppressor cells (MDSCs) in circulating blood were detected by flow cytometry. Compared with model group, both CTX and CTX-TFA can significantly inhibit tumor growth with inhibition rate of 55.61% ($P<0.05$) and 70.91% ($P<0.01$), respectively. However, compared to CTX group, CTX-TFA group showed a higher inhibition rate ($P<0.05$). CTX-TFA group showed an increased percentage of splenic CD3⁺, CD4⁺ T and CD8⁺ T lymphocytes ($P<0.05$, $P<0.01$) and decreased percentage of MDSCs (CD11b⁺Ly6C^{hi}) ($P<0.05$, $P<0.01$), whereas the percentage of CD19⁺ cells remained unchanged. TFA could enhance the anti-tumor effect of CTX and the synergistic effect probably result from improving tumor immune-suppression via increasing the percentage of CD3⁺, CD4⁺ T and CD8⁺ T lymphocytes and down-regulating the percentage of MDSCs.

Keywords: Astragalus flavonoids; breast cancer; cyclophosphamide; immune function

Acknowledgements: This work was supported by grants from Science and Technology Innovation Team of Shanxi Province (No 201605D131045-18) and Key laboratory of Effective Substances Research and Utilization in TCM of Shanxi province (No 201605D111004).

S3.2

Anti-Warburg effect elicited by cAMP-PGC1 α pathway drives differentiation of glioblastoma cells into astrocytes

Wen-bo ZHU¹, Fan XING¹, Jia-luo MAI¹, Jia-yu GU¹, Xin-cheng LIU¹, Wan-jun LU¹, Guang-mei YAN^{1,*}

¹Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China

*To whom correspondence should be addressed.

E-mail: ygm@mail.sysu.edu.cn

Glioblastoma (GBM) is among the most aggressive of human cancers. Although differentiation therapy has been proposed as a potential approach to treat GBM, the mechanisms of induced differentiation remain poorly defined. Here, we established an induced differentiation model of GBM using cAMP activators, which specifically directed GBM into astroglia. Next, transcriptomic and proteomic analyses uncovered oxidative phosphorylation and mitochondrial biogenesis were involved in induced differentiation of GBM. Further investigation showed dbcAMP reversed the Warburg effect evidenced by increase in oxygen consumption and reduction of lactate production. Stimulated mitochondrial biogenesis downstream of CREB/PGC1 α pathway triggered metabolic shift and differentiation. Blocking mitochondrial biogenesis by mdv1 or silencing PGC1 α abrogated differentiation, reversely overexpression of PGC1 α elicited differentiation. In GBM xenograft models and patient-derived GBM samples, cAMP activators also induced tumor growth inhibition and differentiation. This study shows mitochondrial biogenesis and metabolic switch to oxidative phosphorylation drive the differentiation process of tumor cells.

Keywords: differentiation therapy; metabolic reprogramming; Warburg effect; PGC-1 α ; mitochondrial biogenesis

Acknowledgements: This work was supported by grants from the the National Natural Science Foundation of China (No 81673447), the Natural Science Foundation of Guangdong Province, China (No 2014A030313156) and the specific project of science and technology of Guangzhou (No 201607010396).

S3.3

Over-expression of SphK2 contributes to ATRA resistance in colon cancer through rapid degradation of cytoplasmic RXR α by K48/K63-linked polyubiquitination

Wen-na SHI¹, Shu-xiang CUI², Zhi-yu SONG¹, Shu-qing WANG¹, Shi-yue SUN¹, Xin-feng YU¹, Yu-hang ZHANG¹, Zu-hua GAO^{3,*}, Xian-jun QU^{1,*}

¹Department of Pharmacology, School of Basic Medical Sciences, Capital Medical University, Beijing, China; ²Beijing Key Laboratory of Environmental Toxicology, Department of Toxicology and Sanitary Chemistry, School of Public Health, Capital Medical University, Beijing, China; ³Department of Pathology, McGill University, Montreal, Quebec, Canada

*To whom correspondence should be addressed.

E-mail: quxj@ccmu.edu.cn

The resistance mechanisms that limit the efficacy of retinoid therapy in cancer are poorly understood. Sphingosine kinase 2 (SphK2) is a highly conserved enzyme that is mainly located in the nucleus and endoplasmic reticulum. Unlike well-studied sphingosine kinase 1 (SphK1) located in the cytosol, little has yet understood the functions of SphK2. Here we show that SphK2 over-expression contributes to the resistance of all-*trans* retinoic acid (ATRA) therapy in colon cancer through rapid degradation of cytoplasmic retinoid X receptor α (RXR α) by lysine 48 (K48)- and lysine 63 (K63)-based polyubiquitination. Human colonic adenocarcinoma HCT-116 cells transfected with SphK2 (HCT-116^{SphK2} cells) demonstrate resistance to ATRA therapy as determined by *in vitro* and *in vivo* assays. SphK2 over-expression increases the ATRA-induced nuclear RXR α export to cytoplasm and then rapidly degrades RXR α through the poly-ubiquitination pathway. We further show that SphK2 activates the ubiquitin-proteasome system through the signal mechanisms of (1) K48-linked proteasomal degradation and (2) K63-linked ubiquitin-dependent autophagic degradation. These results provide new insights into the biological functions of SphK2 and the molecular mechanisms that underlie the SphK2-mediated resistance to retinoid therapy.

Keywords: sphingosine kinase 2 (SphK2); retinoid therapy resistance; cytoplasmic RXR α ; polyubiquitination; rapid degradation; lysine 48 (K48); lysine 63 (K63)

Acknowledgements: This work was supported by grants from National Natural Science Foundation of China (No 81373436, 81373435 and 91229113) and the Beijing Science Foundation (No 7142017). We thank the Research Institute of the McGill University Health Centre for their financial support.

S3.4

Chemoprevention of intestinal tumorigenesis by the natural dietary flavonoid myricetin and its derivative in APC^{Min/+} mice

Ye LI¹, Shi-yue SUN¹, Zhi-yu SONG¹, Shu-qing WANG¹, Zu-hua GAO², Xian-jun QU¹, Shu-xiang CUI^{3,*}

¹Department of Pharmacology, Capital Medical University School of Basic Medical Sciences, Beijing, China; ²Department of Toxicology and Sanitary Chemistry, School of Public Health, Capital Medical University, Beijing, China; ³Department of Pathology, McGill University, Montreal, Quebec, Canada

*To whom correspondence should be addressed.

E-mail: sxccui@ccmu.edu.cn

Myricetin is a natural dietary flavonoid compound. We evaluated the efficacy of myricetin and its derivative against intestinal tumorigenesis in adenomatous polyposis coli multiple intestinal neoplasia (APC^{Min/+}) mice. Myricetin was given orally once a day for 12 consecutive weeks. APC^{Min/+} mice fed with myricetin developed fewer and smaller polyps without any adverse effects. Histopathological analysis showed a decreased number of dysplastic cells and degree of dysplasia in each polyp. Immunohistochemical and Western blot analysis revealed that myricetin selectively inhibits cell proliferation and induces apoptosis in adenomatous polyps. The effects of myricetin were associated with a modulation the GSK-3 β and Wnt/ β -catenin pathways. ELISA analysis showed a reduced concentration of pro-inflammatory cytokines IL-1 β , IL-6, TNF- α , and PGE₂ in the adenomatous polyps and blood, which were elevated in APC^{Min/+} mice. The effect of myricetin treatment was most prominent in the adenomatous polyps originating in the colon. Further study showed that myricetin down-regulates the phosphorylated p38 MAPK/Akt/mTOR signaling pathways, which may be the mechanisms for the inhibition of adenomatous polyps by myricetin. Taken together, our data show that myricetin inhibits intestinal tumorigenesis through a collection of biological activities. Given these results, we suggest that myricetin could be used preventatively to reduce the risk of developing colon cancers.

Keywords: myricetin; APC^{Min/+} mouse model; intestinal adenomatous polyps; Wnt/ β -catenin pathway; chronic inflammation; p38 MAPK/Akt/mTOR signaling pathways

Acknowledgements: This work was supported by grants from the National Natural Science Foundation of China (No 81373435).

S3.5

The application of "Warburg effect" in chemosensitization—a case report

Yong-ping LIU*, Ya-ping ZHANG, Xi-bao MAO, Qiu-feng QI, Ming ZHU, Yang LING

Department of Oncology Medicine, Changzhou Tumor Hospital Affiliated to Soochow University, Honghe Road No.68, Xinbei Area, Changzhou 213002, China

*To whom correspondence should be addressed.

E-mail: liuyongping026@126.com

Otto Warburg discovered in 1924 that cancer cells are dependent on exclusively glycolysis for production of energy even in the presence of oxygen ("Warburg effect"). The "Warburg effect" is the scientific basis for Positron emission tomography (PET-CT) which has revolutionized cancer detection. During chemotherapy, cancer cells can increase the levels of multi-drug resistance proteins and cause treatments failure. Since multi-drug resistance proteins require energy for its operation, we explored lowering blood glucose by insulin for potential clinical efficacy for chemotherapy of an advanced pulmonary adenocarcinoma patient with multiple metastases. A 64-year-old male was admitted to our department due to irritating cough and multiple bone pain. PET/CT with F-18 fluorodeoxy glucose (FDG) showed multiple hypermetabolic foci in the right hilum, right upper lung, double shoulder blade, thoracic vertebrae, lumbar, sacrum, bilateral iliac crest and the pelvis. The patient received insulin-induced hypoglycemia combined with reduced doses of chemotherapy 56 times. For each treatment, 0.2 units per kilogram of body weight of insulin were injected intravenously. After the blood glucose level reached about 2.5–3.0 mmol/L, navelbine 10 mg, cisplatin 10 mg and 5-FU 250 mg were injected iv during a period of about 10 min. The patient's blood glucose level was returned to normal with iv injection of 20 mL 50% glucose solution. After the eight months of chemotherapy treatments, the patient received two additional PET/CT follow-ups. The results showed that the levels ¹⁸F-FDG uptake in all the lesions has been reduced. In addition, the patient experienced improved appetite, weight gain and reduction of pain and cough. The values of tumor markers also declined gradually. Our results suggest that treatment of controlled, mild hypoglycemia can be safely combined with reduced chemotherapy drugs to provide clinical benefit for a late stage NSCLC patient.

Keywords: Warburg effect; insulin; hypoglycemia; chemotherapy**Acknowledgements:** This study was supported by the Science and Technology Planning Project of Changzhou, Jiangsu Province (No CE20160502).

S3.6

Investigating the platelet-derived growth factor B regulation network in gastric cancer diagnosis and treatment

Wen-guo JIANG*, Fang LIU, Chun-hua YANG, Shu-ping ZHANG, Geng TIAN

Medicine and Pharmacy Research Center, Binzhou Medical University, Guanhai Road, Laishan District, Yantai 264003, China

*To whom correspondence should be addressed.

E-mail: jiangwg@gmail.com

Gastric cancer is one of the most common cancers in Asian countries and is the fourth most commonly occurring cancer worldwide. In the past decade, numerous groups have attempted to profile the expression changes in gastric cancer tissues using proteomic approaches, in search of diagnostic and prognostic biomarkers. However, investigating signalling network with proteomics approach is rarely reported. In this study, we aimed to investigate the PDGFB regulation network in gastric cancer with a label free proteomics approach. To validate the network, the PDGFB was silenced in gastric cancer cells with shRNA based approach. The predicted proteins were validated with Western blot in the PDGFB knockdown cells. To evaluate the effect of PDGFB on gastric cancer cells, cell proliferation was measured in PDGFB knockdown cells. In our study, a total of 2280 unique proteins were identified. Among these, 87 were potentially differentially expressed between gastric cancer and normal gastric tissues. Gastric cancer tissues had an obvious up-regulation of PRDX5, CALR, and CTSD, and a marked down-regulation of S100A6. Furthermore, by applying novel pathway analysis, we found upstream regulators including PDGF-B, PDGFR- β , Akt, eIF4E and p70s6K were obviously increased in the gastric cancer tissues. In addition, silencing of PRDX5 and PDGF-B expression suppressed the proliferation properties of gastric cancer cells *in vitro*. The exogenous PDGF-BB could recover the reduced proteins expression of PDGF-B signaling pathway as PDGF-B knockdown. Our studies suggested that PDGF-B signaling pathway plays an important role in the regulation of gastric cancer proliferation and may be a reasonable approach for treatment of gastric cancer.

Keywords: gastric cancer; quantitative proteomics; label free; PDGFB**Acknowledgements:** This work is supported by the National Natural Science Foundation of China (No 81450049) and the Medical Science and Technology

Development Plan of Shandong Province, China (No 2014WS0486).

S3.7

Quantitative proteomics of transgenic prostate cancer mice reveals that PDGF-B regulatory network plays a key role in prostate cancer progression

Dan WANG, Jia MI, Chun-hua YANG, Shu-ping ZHANG, Bin WANG, Geng TIAN*

Medicine and Pharmacy Research Center, Binzhou Medical University, Yantai 264003, China

*To whom correspondence should be addressed.

E-mail: tiangeng@live.se

Prostate cancer (PCa) is one of the most common cancers in men and is still one of the most intriguing challenge in oncology due to the lack of knowledge of disease progression mechanisms on the molecular and cellular levels. Transgenic adenocarcinoma of the mouse prostate (TRAMP) mice is a widely used transgenic animal model of human prostate cancer (PCa). To investigate the regulatory network associated with PCa progression, we performed a label free quantitative proteomics analysis combined with a careful bioinformatics analysis on the entire prostate protein extraction from TRAMP mice and compared with WT littermates. From totally 2379 identified proteins, we here presented a modest mice prostate reference proteome containing 919 proteins. Biostatistics analysis indicated that 61 proteins presented a significant expression difference between two groups. The subsequent integrative bioinformatics analysis based on both qualitative and quantitative proteomics results predicted the over-expression of the platelet-derived growth factor B (PDGF-B) in tumor tissue and supports the hypothesis of the PDGF-B signaling network as a key upstream regulator in PCa progression. The over-expression of PRDX2, PDIA3, HNRNP1 and PDGF-B in tumor tissues were validated in a small cohort with immune-histochemistry staining ($n=56$) and were further confirmed as three novel PDGF-B-regulating proteins with immunoblot in shRNA-based PDGF-B knockdown PCa cells. Furthermore, we demonstrated that Crenolanib, which is a novel PDGF receptor inhibitor, inhibited PCa cell proliferation in a dose-dependent manner. We revealed the importance of PDGF-B regulatory network in PCa progression, which will assist to understand the role and mechanisms of PDGF-B in promoting the cancer growth and provide valuable knowledge reference in the future research on anti-PDGF therapy.

Keywords: prostate cancer; animal model; quantitative proteomics; PDGFB**Acknowledgements:** This work is supported by Taishan Scholars Construction Engineering; National Natural Science Foundation of China (No 81400771 and 81171303), Shandong Provincial Natural Science Foundation (No ZR2014HL033), Shandong provincial science and technology Plan (No J14LE01 and J15LK03).

S3.8

FOXCl is associated with estrogen receptor and affects sensitivity of tamoxifen treatment in breast cancer Jin-hua WANG¹, Ya-li XU², Xiu-ping CHEN³, Li Li¹, Lin WANG¹, Ru YAO², Qiang SUN², Guan-hua DU^{1*}

¹The State Key Laboratory of Bioactive Substance and Function of Natural Medicines; Beijing Key Laboratory of Drug Target Research and Drug Screen, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100050, China; ²Department of Breast Surgery, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100032, China; ³State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, China

*To whom correspondence should be addressed.

E-mail: dugh@imm.ac.cn

FOXCl is a member of Forkhead box transcription factors that participates in embryonic development and tumorigenesis. Our previous study demonstrated that FOXCl was highly expressed in triple-negative breast cancer. However, it is not clear what relation between FOXCl and ER α is and if FOXCl regulates expression of ER α . To explore relation between FOXCl and ER α and discover regulation of ER α expression by FOXCl in breast cancer, we analysed data assembled in the Oncomine and TCGA, and found that there was significantly higher FOXCl expression in estrogen receptor negative (ER⁻) breast cancer than that in estrogen receptor positive (ER⁺) breast cancer. Overexpression of FOXCl reduced expression of ER α and reduced cellular responses to estradiol (E₂) and tamoxifen in the MCF-7 FOXCl and T47D FOXCl cells while knockdown of FOXCl induced expression of ER α and improved responses to estradiol (E₂) and tamoxifen in BT549 FOXCl shRNA and HCC1806 FOXCl shRNA cells. In addition, overexpression of FOXCl reduced expression of progesterone-receptor (PR), insulin receptor substrate 1 (IRS1) and XBP1 (X-Box Binding Protein 1) and significantly reduced luciferase activity

caused by E₂ using ERE luciferase reporter assay. These results suggested that FOXC1 regulated expression of ER α and affected sensitivity of tamoxifen treatment in breast cancer, and that FOXC1 may be used as a potential drug target in ER α negative breast cancer.

Keywords: breast cancer; estrogen receptor; FOXC1; TCGA; triple negative

Acknowledgements: This work was supported by National Natural Science Foundation of China (No 81573454), Beijing Natural Science Foundation (No 7172142) and CAMS Initiative for Innovative Medicine (CAMS-I2M):2016-I2M-3-007.

S3.9

NRG-1 stimulates DJ-1 secretion from human breast cancers by disassociation from HER3

Yuan-dong WANG¹, Qian LU¹, Yi-ming WANG², Shu ZHANG^{1,*}

¹Clinical Research Center, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China; ²School of Biotechnology and Biomolecular Sciences, University of New South Wales, Kensington, Sydney, NSW 2052, Australia

*To whom correspondence should be addressed.

E-mail: zhangshu@njmu.edu.cn

It is demonstrated that breast cancer cells secrete DJ-1. However, the physiological and pathological significance of DJ-1 secretion is not clearly understood. In fact, a high level of DJ-1 protein has been detected in peripheral blood of patients with breast cancers, which could be a biomarker candidate for breast cancer. We previously found that NRG-1 promoted the decoupling of DJ-1 with HER3 and activated the heterodimerization of HER2/HER3. In this study, we found that the detectable DJ-1 protein expression is decreased, but the HER3 expression is increased, in tumor tissue with the progression of breast cancer disease. There is a significant rise of DJ-1 in the supernatant of MCF-7 cells and in serum *in vitro* after stimulation of NRG-1 in the normal control. Furthermore, we found that the level of DJ-1 in supernatant or serum of HER3 knockdown group was not detected both with and without NRG-1. While DJ-1 level in supernatant or serum of HER3 over-expression group increased significantly than that in normal group with NRG-1 stimulation. These results suggest that NRG-1 improve the exocrine of DJ-1 protein, which was significantly affected by HER3 level *in vivo* and *in vitro*. Moreover, our findings indicate that serum DJ-1 level is a potential serum biomarker for predicting HER3-positive breast cancer patients.

Keywords: serum DJ-1; HER3; NRG-1; breast cancers; MCF-7 cells

Acknowledgements: This work was sponsored by the National Natural Science Foundation of China (No 81102422, 81373398); a Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).

S3.10

Plk1 promotes esophageal squamous cell carcinoma cell metastasis by increasing YAP

Ji-ming LING, Xiao-lin XU, Ji-yu JU, Wei GAO, Chun-ling ZHAO*

Weifang Medical University, Weifang 261042, China

*To whom correspondence should be addressed.

E-mail: zhaochunlingbj@163.com

Polo-like kinase 1 (Plk1), a key regulator of cell cycle progression, is over-expressed in most cancers and can promote proliferation and metastasis. The present study aimed to investigate the function of Plk1 in esophageal squamous cell carcinoma (ESCC) cells metastasis and its potential mechanism. Cell migratory and invasive capabilities were examined by wound scratch assay and Matrigel assay in Eca-109 cells transfected with siPlk1. The pulmonary metastasis model in nude mice were established and treated with siPlk1. The lung metastatic nodules were counted. Immunofluorescence staining and immunoblot were used to explore the expression of E-cadherin, vimentin and Snail. And E-cadherin in the lung metastatic nodules was examined by immunohistochemistry. Expression of total YAP and nuclear YAP were examined by immunoblot. Transcription of CTGF and LYP were also examined by real-time RT-PCR. TE-8 cells were transfected with Plk1 expression plasmid or a combination of Plk1 expression plasmid and siYAP. Cell migratory and invasive capabilities were examined by Transwell assay and Marigel invasion assay. Expression of E-cadherin, vimentin and Snail were examined by immunoblot. Knockdown of Plk1 reduces migratory and invasive capability of ESCC cell lines in *in vitro* or *in vivo*. Loss of Plk1 converts ESCC cell from a mesenchymal phenotype to epithelial phenotype. Reduction of Plk1 results in decrease of total and nuclear Yes-associated protein (YAP), and reduces the transcription of YAP target genes, CTGF and LYP. Furthermore, knockdown of YAP substantially abolishes Plk1 over-expression-induced migration and invasion as well as mesenchymal cell

phenotype. In total, Plk1 plays an important role in ESCC development, and might be a potential therapeutic target for ESCC metastasis.

Keywords: PLK; esophageal squamous cell carcinoma; metastasis; YAP

Acknowledgements: This work was supported by grants from Natural Science Foundation of Shandong Province (No ZR2015HM028) and National Natural Science Foundations of China (No 30901779 and 81572578).

S3.11

Research progress in exosome-mediated interaction between tumor cells and microenvironment

Wei-ying ZHOU^{1,*}

¹School of Pharmacy, Chongqing Medical University, Chongqing 400016, China

*To whom correspondence should be addressed.

E-mail: wyzhou0118@163.com

Exosomes represent a class of cell-derived bilayered membrane-bound nanovesicles defined by size, surface protein and lipid composition, and the ability to carry bio-information. Their contained mRNAs, miRNAs and proteins are important mediators of intercellular communication. Thus, exosomes participate in many normal and pathological processes. They appear to be promising new tools for the clinical diagnostics and potentially for novel therapeutic strategies. More and more studies focus on the roles of exosomes in cancer development, metastasis, drug resistance, diagnosis and cancer treatments. This article bases on my studies on exosome, as well as covers the current evidence concerning exosome-based cancer research.

Keywords: exosomes; cancer; metastasis; therapy resistance; diagnosis; treatment

Acknowledgements: This work was supported by grants from the National Natural Science Foundation of China (No 81472483).

S3.12

The effect and mechanisms of neferine reversal of multi-drug resistance in BEL-7402/CDDP and BEL-7402/FOL cells

Ya-jun ZHOU^{1,2,*}, Jing SHI¹, Liang XIAO¹, Han-xin ZHOU¹, Guo-quan GAO²

¹Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University, Shenzhen 518020, China; ²Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510000, China

*To whom correspondence should be addressed.

E-mail: aquazhou@foxmail.com

The present study aimed to observe the reversing effects of neferine on multidrug resistance of BEL-7402/CDDP and BEL-7402/FOL cells, as well as a preliminary investigation on their mechanism of action. The current clinical regimen FOLFOX4 was used to induce the BEL-7402/FOL cell line by an improved method based on pulsed exposure to chemotherapy drugs in time-step-wise increments and the same method was used in cisplatin-induced CDDP-resistant cell line BEL-7402/CDDP. Drug-resistant cell lines displayed cross-resistance to cisplatin, 5-fluorouracil, oxaliplatin and doxorubicin. Results from the cell counting kit-8 method showed that neferine significantly inhibits the proliferation of parental and drug-resistant cells in a time- and dose-dependent manner. Flow cytometric analysis displayed that neferine induced the cells apoptosis and the further experiment showed that neferine inhibited the cells migration. Subsequently Western blot showed that neferine could downregulate the expression of drug resistance-associated protein (P-gp, MRP1~3) in drug-resistant cells. These results demonstrated that neferine could effectively reverse MDR in drug-resistant cells.

Keywords: neferine; reversion; hepatocellular carcinoma; multidrug resistance

Acknowledgements: This work was supported by grants from the Shenzhen Science and Technology Innovation Committee (No 20160418144001182) and Clinical Doctor-Basic Scientist Combination Foundation of Shenzhen Second People's Hospital.

S3.13

TRPM7 as a potential novel drug target for the treatment of glioblastoma

Raymond WONG^{1,2}, Ekaterina TURLOVA^{1,2}, James RUTKA¹, Zhong-ping FENG^{2,*}, Hong-shuo SUN^{1,2,*}

¹Department of Surgery; ²Department of Physiology, University of Toronto, Toronto, Canada

*To whom correspondence should be addressed.

E-mail: hss.sun@utoronto.ca

Glioblastoma (GBM) is a brain tumor consisting of malignant glial cells, and represents the most aggressive and common cancer originating in the CNS. Prognosis is dismal, and median survival is ~1 year. This poor outcome can in part

be attributed to the lack of effective treatment; the currently used chemotherapeutic agent temozolomide is non-specific, highly cytotoxic, and ineffective. There is an urgent need for new therapeutic agents, which first requires the identification of effective drug targets. TRPM7 aberrant expression has been strongly linked with promoting GBM cellular functions. We previously reported that TRPM7 inhibition suppressed GBM cellular functions.

The aim of this study is to evaluate TRPM7 as a drug target for GBM treatment by potentiating TRPM7 with the recently discovered agonist (naltriben), and examining outcomes of GBM cellular functions (proliferation, migration, and invasion).

With patch-clamp electrophysiology, we observed in the human GBM cell line U87 that naltriben further potentiated the endogenous TRPM7 current. Next, with Fura-2 calcium imaging, we found that there was robust calcium influx in response to naltriben perfusion. GBM cellular functions were then examined with the MTT assay, scratch wound assay, and Matrigel Transwell assay (to assess proliferation,

migration, and invasion, respectively). We found that naltriben significantly enhanced U87 migration and invasion, but not proliferation. To examine the underlying mechanism, we employed Western immunoblotting to detect the protein levels of p-Akt/t-Akt, and p-ERK1 | 2/t-ERK1 | 2. Naltriben-application significantly upregulated ERK signaling, but not Akt signaling.

The current study verifies the involvement of TRPM7 in GBM cellular functions, and provides evidence that TRPM7 activity can potentially be further augmented even in GBM. Treatment options for GBM patients should be considered cautiously in order not to upregulate TRPM7 activity.

Keywords: glioblastoma; GBM; TRPM7; naltriben

Acknowledgements: This work was supported by grants to HSS from the Natural Sciences and Engineering Research Council of Canada (NSERC) Discovery Grants (RGPIN-2016-04574); and to ZPF from the National Sciences and Engineering Research Council of Canada (RGPIN-2014-06471).